Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure Inc. reports developments tied to its U.S. pharmaceutical commercialization business, pharmacy operations, research programs, and public-company governance. The company markets and distributes AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc., and operates pharmacy businesses including Marley Drug, Gateway Medical Pharmacy, and West Olympia Pharmacy.
Recurring updates include quarterly and annual financial results, product revenue from AGGRASTAT and ZYPITAMAG, pharmacy revenue, research and development spending, and the MC-1 program for PNPO deficiency. News also covers completed pharmacy acquisitions, shareholder meeting results, conference calls, and executive leadership changes.
Medicure Inc (TSXV:MPH, OTC:MCUJF) reported its financial results for Q4 and full-year 2024. Total net revenue reached $21.9 million in 2024, slightly up from $21.7 million in 2023. The company's Q4 2024 revenue was $5.9 million, compared to $5.1 million in Q4 2023.
Key performance metrics include:
- AGGRASTAT sales declined to $8.1 million from $9.7 million in 2023
- Marley Drug business revenue increased to $10.8 million from $9.6 million
- ZYPITAMAG total sales grew to $6.2 million from $5.0 million
The company reported a net loss of $1.0 million ($0.10 per share) in 2024, compared to a $922,000 loss in 2023. Adjusted EBITDA was negative $437,000, down from positive $1.9 million. Cash position improved to $7.2 million at year-end 2024, up from $6.4 million in 2023.
Medicure Inc. (TSXV:MPH, OTC:MCUJF), a pharmaceutical company focused on US market development and commercialization, has scheduled its 2024 Year End Financial Results presentation for April 29, 2025, at 8:30 AM ET.
The financial results will be filed after market close on April 28, 2025, followed by a conference call and webcast the next day. The call will include a Q&A session where management will address questions about financial results and operations.
Investors can join via toll-free number 1-877-545-0320 (International: 1-973-528-0002) using participant code 636803. A webcast will be available, and a recording will be posted on the company's website after the event.
Medicure Inc. (TSXV:MPH, OTC:MCUJF) has announced the signing of a definitive agreement to acquire West Olympia Pharmacy Inc. for USD $975,000 through its U.S. subsidiary, Medicure Pharma Inc. The acquisition target generated unaudited revenue of USD $6.8 million and net income of USD $325,000 for the 12-month period ended December 31, 2024.
The acquisition aligns with Medicure's strategic expansion of its direct-to-consumer pharmacy business, following their recent Gateway Pharmacy acquisition. The company aims to accelerate the growth of ZYPITAMAG® and other products, noting that direct-to-consumer sales improve patient access, medication adherence, and reduce distribution costs.
The transaction will be funded through existing cash without requiring financing or debt acquisition. The closing is subject to various conditions, including the transfer of agreements and licenses to Medicure.
Medicure Inc. (TSXV:MPH, OTC:MCUJF) has successfully completed the acquisition of Gateway Medical Pharmacy Inc. through its wholly-owned U.S. subsidiary Medicure Pharma Inc. The transaction, previously announced on February 18, 2025, represents a strategic move to expand Medicure's direct-to-consumer pharmacy business. This acquisition is expected to accelerate the growth of ZYPITAMAG® and other products and services.
The company completed the purchase of 100% of Gateway from an arms-length third-party without requiring any financing or acquiring debt. Additionally, no finder fees were involved in the transaction.
Medicure Inc. (TSXV:MPH)(OTC:MCUJF) has announced the signing of a definitive agreement to acquire Gateway Medical Pharmacy Inc. through its U.S. subsidiary, Medicure Pharma Inc. The agreement, signed on February 14, 2025, represents a strategic expansion of Medicure's direct-to-consumer pharmacy business.
Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024. The acquisition aims to enhance Medicure's ZYPITAMAG® distribution, improve patient access, increase medication adherence, and reduce distribution costs.
The transaction requires no financing or debt acquisition by Medicure, and no finder fees will be paid. The closing is subject to various conditions, including the transfer of agreements and licenses to Medicure.
Medicure reported Q3 2024 financial results with total net revenue of $5.2 million, up from $5.0 million in Q3 2023. AGGRASTAT sales decreased to $1.9 million from $2.4 million, while Marley Drug business revenue increased to $2.7 million from $2.2 million. Net income rose to $680,000 ($0.07 per share) from $84,000 ($0.01 per share) year-over-year. However, adjusted EBITDA turned negative at -$467,000 compared to positive $429,000 in Q3 2023. Cash position decreased to $4.9 million from $6.4 million at year-end 2023.
Medicure (TSXV:MPH)(OTC PINK:MCUJF) has scheduled its Q3 2024 financial results presentation for November 26, 2024, at 8:30 AM ET. The Q3 financials will be filed after market close on November 25, 2024. The company also announced the resignation of Board member Kimberly Kramchynsky, effective November 18, 2024, citing personal reasons. The conference call will be accessible via toll-free and international numbers, with a webcast option available. A Q&A session will follow the presentation, and a recording will be available on the company's website afterward.
Medicure has announced a successful settlement of product development and supply contracts between its subsidiaries Medicure International Inc. & Medicure Pharma Inc. and an undisclosed third party. The company has received a €1.5 million settlement payment as part of the final agreement. The remaining terms of the settlement and the identity of the third party remain confidential.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) reported financial results for Q2 2024. Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023. AGGRASTAT sales declined to $1.8 million from $2.6 million. Marley Drug business revenue remained stable at $2.7 million. ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million. The company reported a net loss of $1.2 million ($0.12 per share) compared to a net income of $253,000 ($0.03 per share) in Q2 2023. Adjusted EBITDA was negative $514,000, down from $948,000. Cash and cash equivalents stood at $5.9 million as of June 30, 2024.
Medicure, a pharmaceutical company, announced an asset purchase agreement with CanAm Bioresearch to acquire patents and intellectual property related to new chemical entities for therapeutic use. Medicure will pay CanAm $100,000 upfront and up to $1.25 million in milestone payments, plus 10% of net proceeds from asset-related transactions, capped at $20 million. The deal includes the option for CanAm to repurchase the assets if Medicure fails to file an IND application within seven years. The agreement remains subject to regulatory approvals and customary closing conditions.